Development of Siglec-8 fusion protein and expression of the protein in HEK & RBL cell lines.
JHU REF: [C11910]
Invention novelty: Development of novel fusion protein Siglec-8 and its expression in animal cell lines HEK and RBL.
Value Proposition:Siglec-8, formerly named SAF-2 is a 431–amino acid protein composed of 3 Ig domains with a 358–amino acid extracellular domain and a 47–amino acid tail. Siglec-8 is highly restricted to eosinophils, basophils, and mast cells, thereby it has applications in detection or modulation of allergic agents and cells. The mammalian cell lines HEK and RBL transfected with Siglec-8 can be used to study Siglec-8 ligands, Siglec-8 function and to screen for binding of anti-Siglec-8 antibodies.
Technical Details:Johns Hopkins University researchers have developed a tangible material which comprises of two components:
1) The creation of a Siglec-8 fusion protein by insertion of the Fc portion of human IgG1 with a factor Xa cleavage site.
2) The subcloning of the protein into the mammalian expression vector pCDN and transfection into HEK293 and RBL cell lines.
Looking for Partners: To develop & commercialize the technology as an immunoassay diagnostic tool for studying allergic cells and agents which trigger allergies.
Stage of Development: Prototype
Data Availability: Animal data
Patent Status: None
Publication(s): Kikly KK, Bochner BS, Freeman SD, Tan KB, Gallagher KT, D'alessio KJ, Holmes SD, Abrahamson JA, Erickson-Miller CL, Murdock PR, Tachimoto H, Schleimer RP, White JR.
Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. J Allergy Clin Immunol. 2000 Jun;105.
